European generic drugmakers call for maintenance of current robust WHO INN system

24 October 2013

The World Health Organization Consultation on International Non-proprietary Names (INN), open session to stakeholders, took place on October 22 in Geneva, Switzerland.

During this session, Joerg Windisch, chief science officer at Swiss drug major Novartis (NOVN: VX) generics unit Sandoz Biopharmaceuticals and chairman of the European Biosimilars Group of the European Generics medicines Association (EGA)Sector Group, highlighted the major contribution that has been made by the WHO to global public health by harmonizing active substance naming internationally.

Fears system could be dismantled amid biosimilars discussions

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >